April 15, 2022
China NMPA Approves BeiGene’s Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
BeiGene, Ltd. has announced that the China National Medical Products Administration (NMPA) has granted approval to BeiGene’s anti-PD-1 antibody, tislelizumab, as a treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have disease progression or are intolerant to first-line standard chemotherapy.
